-$0.49 Earnings Per Share Expected for Autolus Therapeutics plc (NASDAQ:AUTL) This Quarter

Analysts forecast that Autolus Therapeutics plc (NASDAQ:AUTLGet Rating) will announce earnings per share of ($0.49) for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Autolus Therapeutics’ earnings. The highest EPS estimate is ($0.44) and the lowest is ($0.57). Autolus Therapeutics posted earnings of ($0.47) per share during the same quarter last year, which would suggest a negative year-over-year growth rate of 4.3%. The firm is expected to report its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that Autolus Therapeutics will report full year earnings of ($1.98) per share for the current fiscal year, with EPS estimates ranging from ($2.28) to ($1.73). For the next fiscal year, analysts anticipate that the company will post earnings of ($1.98) per share, with EPS estimates ranging from ($2.38) to ($1.60). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side analysts that cover Autolus Therapeutics.

Autolus Therapeutics (NASDAQ:AUTLGet Rating) last announced its quarterly earnings data on Thursday, May 5th. The company reported ($0.41) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.10. Autolus Therapeutics had a negative net margin of 6,098.54% and a negative return on equity of 49.80%. During the same period in the previous year, the firm earned ($0.53) EPS.

Several brokerages have issued reports on AUTL. William Blair reissued an “outperform” rating on shares of Autolus Therapeutics in a research report on Thursday, March 10th. Zacks Investment Research cut Autolus Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, February 21st. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, Autolus Therapeutics presently has an average rating of “Buy” and a consensus price target of $11.75.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. MYDA Advisors LLC grew its position in Autolus Therapeutics by 102.3% during the 3rd quarter. MYDA Advisors LLC now owns 171,953 shares of the company’s stock worth $1,126,000 after purchasing an additional 86,953 shares during the period. Jump Financial LLC lifted its holdings in Autolus Therapeutics by 39.5% in the third quarter. Jump Financial LLC now owns 65,900 shares of the company’s stock valued at $432,000 after acquiring an additional 18,645 shares during the period. Cetera Investment Advisers purchased a new stake in Autolus Therapeutics in the 3rd quarter worth approximately $688,000. Frazier Management LLC grew its stake in shares of Autolus Therapeutics by 6.1% during the 4th quarter. Frazier Management LLC now owns 3,746,857 shares of the company’s stock worth $19,446,000 after purchasing an additional 216,200 shares during the period. Finally, Wealth Effects LLC purchased a new position in shares of Autolus Therapeutics during the 4th quarter valued at approximately $119,000. Institutional investors own 61.45% of the company’s stock.

Autolus Therapeutics stock opened at $2.84 on Thursday. Autolus Therapeutics has a one year low of $2.83 and a one year high of $8.23. The business’s fifty day moving average is $3.89 and its 200 day moving average is $4.77. The stock has a market capitalization of $258.18 million, a PE ratio of -1.53 and a beta of 1.60.

About Autolus Therapeutics (Get Rating)

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma.

Featured Stories

Get a free copy of the Zacks research report on Autolus Therapeutics (AUTL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Autolus Therapeutics (NASDAQ:AUTL)

Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.